Vivoryon Therapeutics NV - Asset Resilience Ratio

Latest as of December 2025: 0.44%

Vivoryon Therapeutics NV (VVY) has an Asset Resilience Ratio of 0.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Vivoryon Therapeutics NV (VVY) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€33.00K

≈ $38.58K USD Cash + Short-term Investments

Total Assets

€7.52 Million

≈ $8.79 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2010–2025)

This chart shows how Vivoryon Therapeutics NV's Asset Resilience Ratio has changed over time. See VVY total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Vivoryon Therapeutics NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Vivoryon Therapeutics NV (VVY) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€33.00K	0.44%
Total Liquid Assets	€33.00K	0.44%

Asset Resilience Insights

Limited Liquidity: Vivoryon Therapeutics NV maintains only 0.44% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Vivoryon Therapeutics NV Industry Peers by Asset Resilience Ratio

Compare Vivoryon Therapeutics NV's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Sagimet Biosciences Inc. Series A Common Stock NASDAQ:SGMT	Biotechnology	63.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	43.36%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bio-Thera Solutions Ltd SHG:688177	Biotechnology	4.09%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Gubra A/S CO:GUBRA	Biotechnology	79.61%

Annual Asset Resilience Ratio for Vivoryon Therapeutics NV (2010–2025)

The table below shows the annual Asset Resilience Ratio data for Vivoryon Therapeutics NV.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.44%	€33.00K ≈ $38.58K	€7.52 Million ≈ $8.79 Million	+0.25pp
2024-12-31	0.19%	€21.00K ≈ $24.55K	€11.28 Million ≈ $13.19 Million	-32.32pp
2023-12-31	32.51%	€10.02 Million ≈ $11.72 Million	€30.83 Million ≈ $36.04 Million	+32.48pp
2022-12-31	0.02%	€7.00K ≈ $8.18K	€31.38 Million ≈ $36.68 Million	-0.01pp
2021-12-31	0.03%	€7.00K ≈ $8.18K	€24.52 Million ≈ $28.67 Million	-0.04pp
2020-12-31	0.07%	€21.00K ≈ $24.55K	€29.75 Million ≈ $34.78 Million	-2.85pp
2013-12-31	2.92%	€186.00K ≈ $217.45K	€6.37 Million ≈ $7.45 Million	+2.90pp
2012-12-31	0.02%	€2.00K ≈ $2.34K	€10.01 Million ≈ $11.70 Million	-5.36pp
2011-12-31	5.38%	€1.03 Million ≈ $1.20 Million	€19.09 Million ≈ $22.32 Million	+5.22pp
2010-12-31	0.17%	€27.00K ≈ $31.57K	€15.97 Million ≈ $18.67 Million	--

pp = percentage points

About Vivoryon Therapeutics NV

AS:VVY Netherlands Biotechnology

Market Cap

$43.28 Million

€37.02 Million EUR

Market Cap Rank

#22990 Global

#83 in Netherlands

Share Price

€1.25

Change (1 day)

+0.40%

52-Week Range

€1.23 - €1.74

All Time High

€26.50